Maximum Strength Pepcid AC Approval Calls For Postmarketing Study
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson/Merck is required to submit a protocol by late March 2004 for a postmarket study on Pepcid AC (famotidine) (10 mg) and new Maximum Strength Pepcid AC (20 mg), following FDA approval of the latter Sept. 24